ave-1642
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT01233895)
Timeline
Indications
Mechanism of action
- Insulin-like growth factor I receptorANTAGONIST
IGF1R antagonist
Inhibits IGF-1 signalling but has no effect on insulin pathway . selectively inhibit the growth of CD45-negative human myeloma cell lines (HMCLs).
IGF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109357 ↗
Also known as
- ave1642
- ave-1642
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00791544 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2008 | Sanofi |
| NCT00774878 | Phase 2 | Oct 1, 2008 | Sanofi, University of Toulouse |
| NCT01233895 | Phase 1 | Sep 1, 2006 | Sanofi |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 2 | 2006 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1